Clinical Trial Update: Open Label, Single Dose, Non-randomized Study to Assess the Drug to Drug Interaction of Briakinumab on CYP Substrates. [Phase 1]

View source ↗

Summary

A Phase 1 open-label, single-dose study evaluating briakinumab's drug-drug interaction with CYP substrates in patients with plaque psoriasis was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Briakinumab (briakinumab)

Snippet

Sponsor: Abbott | Conditions: Moderate to Severe Plaque Psoriasis | Phase 1 | Status: WITHDRAWN